NCT07296536

Expert Consensus on the Use of Isotretinoin in Rejuvenation: A Delphi Study

• Status: Enrolling By Invitation
• Phase: —
• Study type: Observational
• Enrollment: 15 (estimated)
• Sponsor: Venus Research Center · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

This expert consensus project explores the role of low-dose isotretinoin as a rejuvenative and preventive strategy for photoaging and sebaceous-driven skin changes. While isotretinoin is traditionally used for acne, increasing clinical experience suggests that carefully selected micro-dose and low-dose regimens may improve skin texture, pore size, sebaceous activity, and overall skin quality, with potential benefits in skin aging and maintenance rejuvenation programs.

Detailed description

This study is a non-interventional, Delphi-based expert consensus project designed to establish recommendations for the use of isotretinoin in skin rejuvenation. While isotretinoin is primarily indicated for acne, accumulating clinical evidence and practitioner experience suggest that low-dose or micro-dose regimens may contribute to improvements in skin texture, fine lines, pore size, sebaceous activity, and overall skin quality. However, standardized guidance on indications, dosing, treatment duration, monitoring, and safety precautions is limited. A panel of expert dermatologists with practical experience in isotretinoin therapy and skin rejuvenation will be invited to participate in multiple iterative Delphi rounds. Experts will rate agreement with proposed statements using a structured Likert scale. After each round, anonymized feedback will be provided, and statements not reaching consensus will be revised and re-evaluated until stable agreement is achieved. The final output will consist of consensus-based recommendations reflecting practical, safe, and evidence-informed guidance for dermatologists considering isotretinoin for rejuvenation purposes. The study will also identify areas of uncertainty where further research is needed, supporting the safe expansion of isotretinoin applications beyond acne management.

Conditions

• Isotretinoin
• Isotretinoin Adverse Reaction
• Rejuvenation

Timeline

• Start date: 2026-01-25
• Primary completion: 2027-06-01
• Completion: 2027-09-01
• First posted: 2025-12-22
• Last updated: 2025-12-22

Locations

1 site across 1 country: Egypt